Journal Article

Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

Yoshida, Hiroki, Etoh, Takafumi, Furue, Masutaka, Kabashima, Kenji, Hanifin, Jon M, Mlynarczyk, Izabela, Wollenberg, Andreas, Ruzicka, Thomas, Galus, Ryszard, Mihara, Ryosuke, Stewart, Jonathan, Pulka, Grazyna

2017

Overview

In a phase 2, placebo-controlled trial, nemolizumab, an antibody against interleukin-31 receptor A, reduced pruritus in patients with moderate-to-severe atopic dermatitis. These findings support the role of interleukin-31 in the pathophysiology of atopic dermatitis. Atopic dermatitis is a chronic pruritic, inflammatory skin disease that is triggered by an immune response to antigenic substances, irritants, and mechanical irritation and which is often associated with a personal or family history of type 1 allergies, allergic rhinitis, or asthma. 1 – 4 Pruritus often causes patients to persistently scratch their skin, leading to sleep disturbance and exacerbation of atopic dermatitis. Pruritus has a negative effect on the patients’ quality of life, with the intensity of pruritus directly affecting psychosocial well-being. 5 – 9 Some patients have pruritus even if other symptoms are well controlled, and although topical glucocorticoids and antihistamines are . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Antibodies / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Atopic dermatitis / Body weight / Clinical trials / Cytokines / Dermatitis / Dermatitis, Atopic - drug therapy / Drug therapy / Eczema / Edema - chemically induced / Female / Humans / Immunoglobulins / Intention to Treat Analysis / Male / Middle Aged / Patients / Pruritus / Pruritus - drug therapy / Receptors, Interleukin - antagonists & inhibitors / Receptors, Interleukin - immunology / Surface area